In brief: Genzyme; Novo Nordisk

By Staff Writers
Friday, 05 November, 2004

Genzyme will pay Wyeth US$121 million in cash for buy back rights to sell arthritis drug Synvisc in the United States and Europe. Genzyme said additional payments could extend until June 2012 for total payments of US$294 million.

Genzyme said it expects Synvisc to add about $240 million to its sales. It expects the deal to close in January.

Novo Nordisk shares rise on growth drug approval

Shares in Denmark's Novo Nordisk rose as much as 3 per cent on Thursday after the company's growth hormone drug Norditropin had been approved by US health authorities for use on adults.

The US Food and Drug Administration approved the drug Norditropin for adults after having granted approval for its use on children in October.

Related News

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...

Towards safer epilepsy treatment for pregnant women

New research conducted in organoids is expected to provide pregnant women with epilepsy safer...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd